Compare Stocks

→ Move Your Money Before May 1 (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PKPH Peak Pharmaceuticals	$5.50	$2.80	$0.52 ▼ $9.12	$2.16M	0.54	9,053 shs	4 shs
PPCB Propanc Biopharma	$0.00 +10.0%	$0.00	$0.00 ▼ $0.26	$57K	1.74	5.97 million shs	1.68 million shs
RXII RXi Pharmaceuticals	$0.71 +4.4%	$0.42	$0.31 ▼ $7.70	$3.09M	2.07	1.73 million shs	218,621 shs
XBIO Xenetic Biosciences	$4.09 +8.2%	$4.09	$2.55 ▼ $5.97	$6.30M	2.6	5,801 shs	665 shs

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PKPH Peak Pharmaceuticals	0.00%	+29.41%	+86.76%	+146.64%	+23.87%
PPCB Propanc Biopharma	+10.00%	+10.00%	-59.26%	-79.63%	-99.69%
RXII RXi Pharmaceuticals	0.00%	+5.21%	-8.08%	+11.83%	-79.97%
XBIO Xenetic Biosciences	-1.92%	-5.60%	-2.43%	+14.77%	-12.29%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PKPH Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RXII RXi Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PKPH Peak Pharmaceuticals	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A
RXII RXi Pharmaceuticals	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	2.00	Hold	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PKPH Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	($0.52) per share	N/A
RXII RXi Pharmaceuticals	$10K	309.23	N/A	N/A	$0.77 per share	0.92
XBIO Xenetic Biosciences	$2.54M	2.48	N/A	N/A	$6.36 per share	0.64

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PKPH Peak Pharmaceuticals	-$160K	N/A	0.00	∞	N/A	N/A	N/A	-159.55%	N/A
PPCB Propanc Biopharma	-$2.66M	N/A	0.00	∞	N/A	N/A	N/A	-1,592.49%	N/A
RXII RXi Pharmaceuticals	-$12.45M	-$4.20	N/A	N/A	N/A	-4,990.20%	-412.15%	-179.54%	N/A
XBIO Xenetic Biosciences	-$4.14M	-$2.75	N/A	N/A	N/A	-162.84%	-36.43%	-33.74%	5/9/2024 (Estimated)

Latest XBIO, RXII, PKPH, and PPCB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	XBIO Xenetic Biosciences	-$0.87	-$0.77	+$0.10	-$0.77	$0.68 million	$0.67 million
2/20/2024	Q2 2024	PPCB Propanc Biopharma	N/A	-$0.03	-$0.03	-$0.03	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PKPH Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	N/A
RXII RXi Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PKPH Peak Pharmaceuticals	N/A	0.15	0.15
PPCB Propanc Biopharma	N/A	0.06	0.06
RXII RXi Pharmaceuticals	N/A	1.77	1.77
XBIO Xenetic Biosciences	N/A	11.84	11.84

Ownership

Institutional Ownership

Company	Institutional Ownership
PKPH Peak Pharmaceuticals	N/A
PPCB Propanc Biopharma	N/A
RXII RXi Pharmaceuticals	9.64%
XBIO Xenetic Biosciences	15.12%

Insider Ownership

Company	Insider Ownership
PKPH Peak Pharmaceuticals	18.40%
PPCB Propanc Biopharma	1.80%
RXII RXi Pharmaceuticals	1.01%
XBIO Xenetic Biosciences	9.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
PKPH Peak Pharmaceuticals	1	392,000	320,000	Not Optionable
PPCB Propanc Biopharma	1	52.15 million	51.21 million	Not Optionable
RXII RXi Pharmaceuticals	N/A	4.38 million	N/A	Not Optionable
XBIO Xenetic Biosciences	4	1.54 million	1.40 million	Not Optionable

XBIO, RXII, PKPH, and PPCB Headlines

Source	Headline
	Xenetic Biosciences Inc (XBIO) investing.com - April 10 at 3:28 PM
	Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - March 24 at 5:09 PM
	Xenetic Dips on Full-Year Results baystreet.ca - March 22 at 7:33 PM
	Xenetic Biosciences reports FY results msn.com - March 22 at 8:51 AM
	Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results accesswire.com - March 22 at 8:00 AM
	Xenetic to advance DNase programme with UVA partnership msn.com - January 18 at 1:37 PM
	Xenetic Biosciences Inc XBIO morningstar.com - January 4 at 5:10 PM
	Xenetic Biosciences Stock (NASDAQ:XBIO), Guidance and Forecast benzinga.com - December 11 at 9:01 AM
	Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation finance.yahoo.com - November 30 at 10:39 AM
	Xenetic Biosciences: Q3 Earnings Insights benzinga.com - November 10 at 3:38 PM
	MediciNova: Q3 Earnings Snapshot washingtonpost.com - November 10 at 10:37 AM
	Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference finance.yahoo.com - October 11 at 9:30 AM
	Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock? msn.com - July 13 at 1:44 PM
	Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - May 11 at 5:06 PM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison \| Morningstar morningstar.com - May 5 at 10:21 AM
	Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development finance.yahoo.com - May 4 at 10:02 AM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison finance.yahoo.com - May 3 at 10:26 AM
	HC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy Recommendation msn.com - April 12 at 10:37 PM
	Xenetic Biosciences forms research collaboration with TSRI pharmaceutical-technology.com - April 12 at 12:36 PM
	Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO) markets.businessinsider.com - April 12 at 2:30 AM
	Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform finance.yahoo.com - April 11 at 8:43 AM
	JTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finanznachrichten.de - March 16 at 12:09 PM
	JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finance.yahoo.com - March 16 at 12:09 PM
	XBIO Xenetic Biosciences, Inc. seekingalpha.com - February 23 at 11:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Peak Pharmaceuticals

OTCMKTS:PKPH

Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.

Propanc Biopharma

OTCMKTS:PPCB

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

RXi Pharmaceuticals

NASDAQ:RXII

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Xenetic Biosciences

NASDAQ:XBIO

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial